Daclatasvir

DAKLINZA

Pronunciation: dak-LAT-as-veer

What it isCYP3A4-metabolized HCV NS5A replication-complex inhibitor.

Why this oneGiven with sofosbuvir (with or without ribavirin) for pan-genotypic chronic hepatitis C, including decompensated cirrhosis.

What limits itNeeds dose adjustment with strong CYP3A inhibitors/inducers and can cause symptomatic bradycardia when combined with amiodarone.

Daclatasvir prescription history

Animated chart of estimated U.S. prescriptions per year, Hepatitis C meds (1987–2026). Daclatasvir enters in 2015 (estimated).

⚠ BOXED WARNING

Principal riskBoxed warning: risk of hepatitis B virus reactivation in HCV/HBV co-infected patients, sometimes fulminant.

Therapeutic safety burden2 / 4

Overdose danger1 / 4

Sedation liability1 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Which antiviral is paired with daclatasvir?
Sofosbuvir, with or without ribavirin.
Which antiarrhythmic combination can cause symptomatic bradycardia?
Amiodarone.